SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted To SLS009 For The Treatment Of Pediatric Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that the U.S. FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug SLS009 for the treatment of pediatric acute myeloid leukemia (AML). This designation makes SLS009 eligible for a Priority Review Voucher (PRV) upon marketing approval, which can be transferred or sold.
July 16, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) received FDA Rare Pediatric Disease Designation for SLS009, making it eligible for a Priority Review Voucher upon marketing approval. This is a significant regulatory milestone that could positively impact the company's stock price.
The FDA's Rare Pediatric Disease Designation is a significant regulatory milestone that can lead to a Priority Review Voucher, which is highly valuable and can be sold or transferred. This news is likely to positively impact SELLAS' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100